AIM ImmunoTech Announces $2.4 Million Financing, Including Concurrent Registered Direct Offering and Private Placement

AIM ImmunoTech Inc. announced a $2.4 million financing consisting of a registered direct offering of 7.5 million shares at $0.325 per share and concurrent private placement of Series I Warrants to purchase 15 million shares. The company plans to use proceeds for manufacturing clinical drug supply, Phase 3 clinical trial activities, and working capital. The offering is expected to close on May 21, 2026.